The changing role of radiotherapy in AIDS-related malignancies

Clinical Oncology

Volumn 15, Issue 1, 2003, Pages 2-6

  Lukawska, J ^a   Cottrill, C ^b   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; DANAZOL; FOLINIC ACID; IMMUNOGLOBULIN; METHOTREXATE; STRONTIUM 90;

AIDS RELATED COMPLEX; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANUS CANCER; ARTICLE; BONE MARROW TOXICITY; BRACHYTHERAPY; BRAIN LYMPHOMA; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; KAPOSI SARCOMA; MALE; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; META ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; RADIATION INJURY; SPLENECTOMY; UNITED KINGDOM; UTERINE CERVIX CANCER;

EID: 12244290967     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2002.0100     Document Type: Article

References (44)

1. Cottrill CP, Bottomley D, Phillips RH. Cancer and HIV infection. Clin Oncol (R Coll Radiol) 1997;9:355-356.
2. Friedman-Kien A, Laubenstein L, Marmor M, et al. Kaposi's sarcoma and pneumocystis pneumonia among homosexual men - New York and California. Morbid Mortal Week Rep 1981;30: 250-254.
3. International collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92: 1823-1830.
4. Mocroft A, Katlama C, Johnson A, et al. AIDS across Europe 1994-1998: the EuroSIDA study. Lancet 2000;356:291-296.
5. Mocroft A, Sabin C, Youle M, et al. Changes in AIDS-defining illnesses in a London Clinic 1987-1998. J Acquir Immune Defic Syndr 1999;21:401-407.
6. Conant MA, Opp KM, Poretz D, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS 1997;11:1300-1301.
7. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997;11:261-262.
8. Vaccher E, di Gennaro G, Nasti G, et al. HAART is effective as anti-Kaposi's sarcoma therapy only after remission has been induced by chemotherapy. J Acquir Immune Defic Syndr 1999;22(4):407-408.
9. Winceslaus J. Regression of AIDS-related pleural effusion with HAART. Highly active antiretroviral therapy. Int J STD AIDS 1998;9:368-370.
10. Bower M, Fox P, Fife K, et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure (TTF) in Kaposi's sarcoma. AIDS 1999;13:2105-2111.
11. Osman M, Kubo R, Gill J, et al. Identification of HHV-8 specific cytotoxic T cell responses. J Virol 1999;73:6136-6140.
12. Stelzer KTG. A randomised prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. Int J Radiat Oncol Biol Phy 1993;27:1057-1061.
13. de Wit R, Smit W, Veenhof K, et al. Palliative radiation therapy for AIDS-associated Kaposi's sarcoma by using a single fraction of 800 cGy. Radiother Oncol 1990;19:131-136.
14. Berson A, Quivey J, Harris J, et al. Radiation therapy for AIDS-related Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1990;19:569-575.
15. Geara F, Le Bourgeois J, Piedbois P, et al. Radiotherapy in the management of cutaneous Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1991;21:1517-1522.
16. Watkins E, Findlay P, Gelmann E, et al. Enhanced mucosal reactions in AIDS patients receiving orophanryngeal irradiation. Int J Radiat Oncol Biol Phys 1987;13:1403-1408.
17. Formenti S, Chak L, Gill P, et al. Increased radiosensitivity of normal tissue fibroblasts in patients with acquired immunodeficiency syndrome (AIDS) and with Kaposi's sarcoma. Int J Radiat Biol 1995;68:411-412.
18. Le Bourgeois J, Frikha H, Piedbois P, et al. Radiotherapy in the management of epidemic Kaposi's sarcoma of the oral cavity, the eyelid and the genitals. Radiother Oncol 1994;30:263-266.
19. Ghabrial R, Quivey J, Dunn J, et al. Radiation therapy of acquired immunodeficiency related Kaposi's sarcoma of the eyelids and conjunctiva. Arch Ophthalmol 1992;110:1423-1426.
20. Brunt MRP. Strontium-90 for conjunctival AIDS-related Kaposi's sarcoma: the first case report. Clin Oncol 1990;2:118-119.
21. Beral V, Peterman T, Berkelman R, et al. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337:805-809.
22. Bigger RJ, Rosenberg PS, Cote T. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS, Multistate AIDS/Cancer Match Study Group. Int J Cancer 1996;68: 754-758.
23. Matthews G, Bower M, Mandalia S, et al. Changes in AIDS-related lymphoma since the introduction of HAART. Blood 2000;96:2730-2734.
24. Jacomet C, Girard P, Lebrette M, et al. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997;11:1725-1730.
25. Sparano JA, Lee S, Henry DH, et al. 0Infusional cyclophosphamide, doxorubicin and etoposide in HIV associated non-Hodgkin's lymphoma: A review of the Einstein, Aviano and ECOG experience in 182 patients. J AIDS 2000;23:A11.
26. Chow KU, Mitrou PS, Geduldig K, et al. Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001;41:105-116.
27. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112:909-915.
28. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91:155-163.
29. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-1491.
30. Maiman M, Fruchter R, Guy L, et al. Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 1993;71:402-406.
31. Goedert J, Cote T, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833-1839.
32. Soulier J, Grollet L, Oksenhendlder E, et al. Kaposi's sarcoma-associated Herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276-1280.
33. Frisch M, Biggar R, Goedert J, et al. Human Papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-1510.
34. Lorenz HP, Wilson W, Leigh B, et al. Squamous cell carcinoma of the anus and HIV infection. Dis Colon Rectum 1991;34:336-338.
35. Svensson C, Kaigas M, Lidbrink E, et al. Carcinoma of the anal canal in a patient with AIDS. Acta Oncol 1991;30:986-987.
36. Peddada AV, Smith DE, Rao AR, et al. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1997;37:1101-1105.
37. Cleator S, Fife K, Nelson M, et al. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer 2000;36:754-758.
38. Powles T, Nelson M, Mandalia S, Gazzard B, Bower M. HIV related lung cancer in the pre and post HAART era. HIV Medicine 2002 (in press).
39. Marroni M, Sinnone MS, Landonio G, et al. Splenic irradiation versus splenectomy for severe, refractory HIV-related thrombocytopenia: effects on platelet counts and immunological status. AIDS 2000; 14:1664-1667.
40. Blauth J, Fisher S, Henry D, Nichini F. The role of splenic irradiation in treating HIV-associated immune thrombocytopenia. Int J Radiat Oncol Biol Phys 1999;45:457-460.
41. EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001;15:309-320.
42. Weistenstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001;134:440-450.
43. Mackall C. T-cell immunodeficiency following cytotoxic anti-neoplastic therapy: a review. 18:10-18. Stem Cells 2000;
44. Powles T, Imami N, Nelson M, et al. The effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV associated lymphoma. AIDS 2001 (in press).